Abstract: TH-PO690
Incidence of Primary Immunoglobulin A Nephropathy (IgAN) Among a Diverse Population in the United States
Session Information
- Glomerular Diseases: Epidemiology and Case Reports
November 02, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Trials
Authors
- Sim, John J., Kaiser Permanente Southern California, Pasadena, California, United States
- Chen, Qiaoling, Kaiser Permanente Southern California, Pasadena, California, United States
- Chang, John M., Kaiser Permanente Southern California, Pasadena, California, United States
- Cannizzaro, Nancy, Kaiser Permanente Southern California, Pasadena, California, United States
- Makhija, Dilip, Otsuka America Pharmaceutical Inc, Rockville, Maryland, United States
- Fernandes, Ancilla, Otsuka America Pharmaceutical Inc, Rockville, Maryland, United States
- Bhattacharjee, Sandipan, Otsuka America Pharmaceutical Inc, Rockville, Maryland, United States
- Pinto, Cibele S., Otsuka America Pharmaceutical Inc, Rockville, Maryland, United States
- Schachter, Asher Daniel, Visterra Inc, Waltham, Massachusetts, United States
- Mathur, Mohit, Visterra Inc, Waltham, Massachusetts, United States
Background
IgAN is a leading cause of primary glomerular disease and end stage kidney disease (ESKD) with a 10-year risk of chronic kidney disease (CKD) progression of up to 40%. Global incidence is estimated at 2-5 cases per 100,000 people. US data suggest lower rates but varies by race/ethnicity. We examined incidence of primary IgAN, leveraging a diverse, contemporary cohort from a single integrated health system in California.
Methods
A retrospective cohort was studied (1/1/2010-12/31/2021) of Kaiser Permanente members with biopsy proven IgAN, excluding secondary IgAN. Annual IgAN incidence rates were standardized by age, sex, and race/ethnicity according to the 2020 US Census using the American Community Survey (ACS). Primary IgAN rate was calculated for 2010-2021 and stratified by race/ethnicity. We estimated IgAN prevalence by using mean annual incidence x estimated disease duration.
Results
A total of 606 primary IgAN patients were identified with mean age (SD) of 46 years (15.0) with males (51.2%), Hispanic/Latinos (38.6%), Asian/Pacific Islanders (30.4%), Whites (25.6%), and Blacks (3.1%). The average annual incidence rate (per 100,000 person-years) of primary IgAN was 4.5, 1.7, 1.2, and 0.6 among Asian/Pacific Islanders, Hispanic/Latino, Whites, and Blacks, respectively. The mean annual IgAN incidence of 1.4 per 100,000 person-years equates to an adjusted IgAN prevalence estimate of 40 per 100,000 persons (incidence x estimated disease duration of 28.5 years for IgAN patients).
Conclusion
Our findings show a mean annual IgAN incidence of 1.4 per 100,000 person-years. Asian/Pacific Islander and Hispanic/Latino had the highest incidence rate of IgAN. Whether the clinical course and response to treatment for IgAN patients varies by race/ethnicity warrants further investigation.
Funding
- Commercial Support – Otsuka Pharmaceuticals